Skip to main content
MoonLake Immunotherapeutics logo

MoonLake Immunotherapeutics — Investor Relations & Filings

Ticker · MLTX ISIN · KY61559X1045 US Manufacturing
Open in API
Filings indexed 284 across all filing types
Latest filing 2026-06-01 Regulatory Filings
Country US United States of America
Listing US MLTX

About MoonLake Immunotherapeutics

https://moonlaketx.com/

MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company that develops therapies for inflammatory and immunologic diseases by leveraging Nanobody® technology. The company's lead investigational asset is sonelokimab, a Nanobody designed to target key inflammatory pathways. MoonLake is advancing sonelokimab through late-stage clinical development, with Phase 3 programs (VELA and IZAR) underway for the treatment of hidradenitis suppurativa (HS) and psoriatic arthritis (PsA). The company focuses on addressing conditions with significant unmet medical needs.

Recent filings

Filing Released Lang Actions
CURRENT REPORT
Regulatory Filings Classification · 90% confidence The provided document is a Form 8-K “Current Report” under the Securities Exchange Act of 1934, describing the entry into material definitive agreements. It is not an annual (10-K) or quarterly/interim report (IR), not a merger proxy (MA/TAR), not an earnings release (ER), and contains no actual financial statements or substantial ESG content. Form 8-K filings are general regulatory compliance reports, so it falls under the fallback category of Regulatory Filings (RNS).
2026-06-01 English
10-Q - MoonLake Immunotherapeutics (0001821586) (Filer)
Interim / Quarterly Report Q1 2026
2026-05-11 English
8-K - MoonLake Immunotherapeutics (0001821586) (Filer)
Regulatory Filings
2026-05-11 English
10-K - MOONLAKE IMMUNOTHERAPEUTICS (0001821586) (Filer)
Annual Report FY 2025
2026-02-25 English
8-K - MoonLake Immunotherapeutics (0001821586) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated February 18, 2026, for MoonLake Immunotherapeutics. It includes multiple items such as entry into a material definitive agreement (an amended loan and security agreement), results of operations and financial condition (with a press release attached), creation of a direct financial obligation, departure and appointment of directors, and regulation FD disclosure including clinical trial results and financial results for the year ended December 31, 2025. The document is a regulatory filing that reports significant corporate events and financial updates but does not itself contain comprehensive financial statements or detailed financial analysis typical of an Annual Report (10-K) or Interim Report (IR). It is not a press release alone, nor a transcript, nor a proxy statement. Given the nature of Form 8-K filings as current reports disclosing material events, the appropriate classification is Regulatory Filings (RNS).
2026-02-23 English
SCHEDULE 13G Filing
Major Shareholding Notification
2026-02-17 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.